Moderna’s shares fell 4.8% in pre-market trading after the company announced plans to raise up to $2 billion through a restricted offering of senior convertible notes maturing in 2032. Initial purchasers were granted an option to acquire an additional $300 million in securities, according to a filing.
The capital raise, intended to strengthen Moderna’s balance sheet, follows a recent surge in its stock price to a 52-week high of $176.66 on August 19. That gain coincided with positive Phase 3 results for intismeran, a personalized mRNA cancer vaccine developed in partnership with Merck. Despite the promising clinical update, the company’s second-quarter 2026 performance showed revenue of $145 million alongside a net loss of $782 million.
Analysts at Wolfe Research upgraded Moderna’s rating from Underperform to Peer Perform, though the firm’s price target remained below recent trading levels. This signaled that the stock’s rally had potentially outpaced its underlying fundamentals. The decline in Moderna’s shares occurred amid a broader market advance, with the S&P 500 up 0.4% and the Nasdaq gaining 1.0%. Peer biotech firms, including BioNTech and Merck, also experienced declines in line with Moderna’s correction.
The drop reflects investor concern over dilution risk associated with the convertible note offering, compounded by ongoing profitability challenges despite progress in its oncology pipeline.
